Non-interventional Study With Nab-Paclitaxel (Abraxane®) (NABUCCO)
Non-Interventional Study to Investigate Efficacy and Safety of Nab-Paclitaxel in Patients With Metastatic Breast Cancer
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
The main focus of this non-interventional study is set on answering the following questions:
- Can the results observed in controlled clinical trials regarding efficacy and safety be reproduced in the routine clinical setting?
- Are the side-effects of nab-paclitaxel therapy observed in this study comparable to the previously described safety-profile in terms of frequency and intensity?
- What are the main reasons for modification or termination of the nab-paclitaxel therapy?
- How does nab-paclitaxel therapy influence the patients' quality of life?
- What are the criteria for selecting nab-paclitaxel as therapy for metastatic breast cancer?
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Baden-Wuerttemberg
-
Freiburg, Baden-Wuerttemberg, Germany, 79108
- iOMEDICO AG
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Female Patients with metastatic breast cancer, who are at least 18 years old (no upper age limit)
Exclusion Criteria:
- Contraindication according to the summary of product characteristics of Abraxane®
- No signed patient informed consent form available
- pregnant or breastfeeding patients.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Adult female patients with MBC
This is an observational study, no interventions are specified
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Time to Tumor Progression (TTP)
Time Frame: 6 months after last-patient-in (LPI)
|
6 months after last-patient-in (LPI)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Response Rate (ORR)
Time Frame: 6 months after last-patient-in (LPI)
|
6 months after last-patient-in (LPI)
|
|
|
Overall survival (OS)
Time Frame: 6 months after last-patient-in (LPI)
|
6 months after last-patient-in (LPI)
|
|
|
Time to treatment discontinuation
Time Frame: 6 months after last-patient-in (LPI)
|
6 months after last-patient-in (LPI)
|
|
|
Number of participants with Adverse Events as a measure of safety and tolerability
Time Frame: Until 30 days after discontinuation of Nab-paclitaxel
|
Until 30 days after discontinuation of Nab-paclitaxel
|
|
|
Relative dosage of Nab-Paclitaxel
Time Frame: Until discontinuation of Nab-Paclitaxel, up to 6 month
|
Until discontinuation of Nab-Paclitaxel, up to 6 month
|
|
|
Intensity of peripheral neuropathy
Time Frame: Until discontinuation of Nab-Paclitaxel, up to 6 month
|
Until discontinuation of Nab-Paclitaxel, up to 6 month
|
|
|
Occurence of neutropenia
Time Frame: Until discontinuation of Nab-Paclitaxel, up to 6 month
|
Until discontinuation of Nab-Paclitaxel, up to 6 month
|
|
|
Necessity of supportive medication (e.g. haematopoetic growth factors, analgetics, antibiotics and antiemetics)
Time Frame: Until discontinuation of Nab-Paclitaxel, up to 6 month
|
Until discontinuation of Nab-Paclitaxel, up to 6 month
|
|
|
Patient reported outcome on Quality of life and adverse events
Time Frame: At baseline, 3 and 6 months after start of treatment
|
Assessed by questionnaires FACT-G, FACT-B, FACT-Taxanes and a pain questionnaire of the Robert-Koch-Institute.
|
At baseline, 3 and 6 months after start of treatment
|
|
Reasons for dose modifications or discontinuation of treatment
Time Frame: Until discontinuation of Nab-Paclitaxel, up to 6 month
|
Until discontinuation of Nab-Paclitaxel, up to 6 month
|
|
|
Occurence of febrile neutropenia
Time Frame: Until discontinuation of Nab-Paclitaxel, up to 6 month
|
Until discontinuation of Nab-Paclitaxel, up to 6 month
|
|
|
Occurence of peripheral neuropathy
Time Frame: Until discontinuation of Nab-Paclitaxel, up to 6 month
|
Until discontinuation of Nab-Paclitaxel, up to 6 month
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Christoph Salat, Prof., Haemato-Onkologische Schwerpunktpraxis Franz-Schrank-Strasse 2 80638 Munich, Germany
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IOM-02240
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.